Skip to content 
Cardiovascular Clinical Trials: The Research Changing Heart Health Forever
You may already be on a statin — but research is proving that controlling cholesterol goes much further than
most patients realize.
According to the CDC, Heart disease remains the number one killer of Americans — responsible for one death every 34 seconds. And despite the widespread use of statin medications, millions of patients on treatment still experience heart attacks and strokes. Why? Because LDL cholesterol is not the only player in cardiovascular risk, and statins are not effective for everyone. Cardiovascular clinical trials are now targeting cholesterol pathways that statins cannot reach — and the results from recent trials are changing the way cardiologists and primary care physicians think about heart disease prevention.
Beyond LDL: The Cholesterol Numbers Your Doctor May Now Be Watching
Most patients know their LDL (“bad” cholesterol) and HDL (“good” cholesterol) numbers. But cardiovascular risk research has identified additional markers that matter significantly:
-
Lipoprotein(a) — or Lp(a) — a genetically determined particle that dramatically increases heart attack and stroke risk and is not lowered by statins
- ApoB — a more precise measure of atherogenic particle count than LDL alone
- Triglycerides — elevated levels, often driven by diet and metabolic dysfunction, that contribute to plaque formation independently of LDL
- Non-HDL cholesterol — a broader measure increasingly used to guide treatment decisions
1 in 5 Americans has elevated Lp(a) — a major cardiovascular risk factor not addressed by standard statin therapy and not routinely tested.
Cardiovascular Clinical Trials Studying Cholesterol Right Now
Several of the most exciting cardiovascular trials currently enrolling patients are targeting cholesterol reduction in ways that go beyond statins:
- PCSK9 inhibitors and RNA-based therapies that dramatically lower LDL — even in statin-intolerant patients
- RNA-targeting agents (inclisiran and similar) that reduce LDL with twice-yearly dosing
- First-generation therapies specifically targeting Lp(a) — an area that has had no effective treatment until now
- Combination metabolic therapies that lower both blood sugar and cardiovascular risk simultaneously
Who Should Consider a Cardiovascular Research Study
You may be an ideal candidate for a cardiovascular clinical research if:
- You have high LDL despite taking a statin, or cannot tolerate statin therapy
- You have been told your Lp(a) is elevated
- You have a personal or family history of early heart disease
- You have Type 2 diabetes or metabolic syndrome and are at elevated cardiovascular risk
- Your triglycerides remain high despite lifestyle modification and medication
The Intersection of Heart Health and Metabolic Disease
One of the most important insights from recent cardiovascular research is how deeply interconnected heart disease and metabolic disease are. Insulin resistance drives inflammation in arterial walls. Elevated triglycerides and low HDL create atherogenic conditions. Obesity strains the heart mechanically and biochemically.
This is why primary care physicians — who manage the full picture of a patient’s metabolic health — are increasingly central to cardiovascular risk reduction. And it is why community-based research sites that specialize in metabolic conditions are uniquely positioned to offer cardiovascular trials to the patients who need them most.
This is why primary care physicians — who manage the full picture of a patient’s metabolic health — are increasingly central to cardiovascular risk reduction. And it is why community-based research sites that specialize in metabolic conditions are uniquely positioned to offer cardiovascular trials to the patients who need them most.
Controlling cholesterol is not a one-size-fits-all equation. If your numbers are not where they should be despite current treatment, a clinical trial may offer the next step.
Understanding Cholesterol and Your Risk for Heart Disease
Here are answers to common questions patients ask about cholesterol, heart disease risk, and cardiovascular
clinical trials.
What cholesterol numbers matter for heart disease risk beyond LDL?
While LDL (“bad” cholesterol) is the most commonly tracked marker, cardiovascular research has identified
several additional risk factors: Lipoprotein(a) or Lp(a), a genetically determined particle not lowered by statins;
ApoB, a more precise measure of atherogenic particles; elevated triglycerides; and non-HDL cholesterol. One in
five Americans has elevated Lp(a) — a significant cardiovascular risk factor that is not addressed by standard
statin therapy and is not routinely tested.
What new cholesterol treatments are being studied in clinical trials?
Current cardiovascular trials are targeting cholesterol reduction beyond what statins can achieve. Studies are
enrolling patients for PCSK9 inhibitors, RNA-based therapies that dramatically lower LDL with twice-yearly
dosing, and first-generation treatments specifically targeting Lp(a) — a risk factor that has had no effective
treatment until now. Combination metabolic therapies that simultaneously lower blood sugar and
cardiovascular risk are also actively being studied.
Who qualifies for a cardiovascular clinical trial?
Ideal candidates include adults with high LDL despite statin use, those who cannot tolerate statin therapy,
patients with elevated Lp(a), individuals with a personal or family history of early heart disease, and those with
Type 2 diabetes, metabolic syndrome, or persistently high triglycerides. Mission Research Institute located in the
heart of Arizona offers access to these investigational treatments at no cost, often years before they become
standard care.
